Streamex Corp 8-K, filed Apr 15, 2021
Streamex Corp. (STEX)
About this 8-K
Streamex Corp filed this 8-K on April 15, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) | Identification No.) |
| | | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
|
N/A (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| | | The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On April 15, 2021, BioSig Technologies, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that it added two experienced electrophysiology Regional Directors to lead commercial expansion across Southeast and Central regions. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
|
99.1 |
Press Release, dated April 15, 2021 (furnished herewith pursuant to Item 7.01) |
|
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSIG TECHNOLOGIES, INC. |
|||
|
Date: April 15, 2021 |
By: |
/s/ Kenneth L. Londoner |
|
|
Name: Kenneth L. Londoner |
|||
|
Title: Executive Chairman |
|||
Exhibit 99.1
BioSig Expands Commercial Team in Two Strategic Regions
Two seasoned MedTech sales executives join the Company to lead regional rollouts of the PURE EP System™, an electrophysiology system for arrhythmia procedures
Westport, CT, April 15, 2021 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it added two experienced electrophysiology Regional Directors to lead commercial expansion across Southeast and Central regions.
Mr. Robert Sandler, appointed to lead regional sales across Texas, brings to the Company over 25 years of sales experience in medical devices. Before joining BioSig, Mr. Sandler led regional sales at CardioFocus, Inc. and Cardiva Medical, Inc. Earlier in his career, he was responsible for the Dallas market at Biosense Webster, a Johnson&Johnson company.
Mr. Timothy Jones, appointed to lead regional sales across Florida, has over 20 years of medical equipment sales and sales management experience. Previously, Mr. Jones led high-performing commercial teams at CR Bard for Bard Electrophysiology and Bard Access Systems. Most recently, Mr. Jones was employed by Boston Scientific Corp., where he led regional sales for its Augmenix division.
"We are very pleased to welcome Rob and Tim to our expanding commercial team. Their combined industry expertise, proven track record in medical device sales, and strong relationships in the Texas and Florida electrophysiology markets will allow us to accelerate our commercial sales in these strategically important regions,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
With over 350 electrophysiology labs, Florida and Texas offer some of the largest clinical footprints in the country. BioSig’s PURE EP™ System is currently installed in eight medical centers of excellence across the country, including Mayo Clinic Florida Campus in Jacksonville, Florida, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX, and Houston Methodist Hospital in Houston, TX. The Company previously announced that it completed commercial sales to St. David’s HealthCare and Mayo Foundation for Medical Education and Research. The Company expects to triple its customer base in 2021.
One in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
1Top 10 Things You should Know About Heart Rhythm; Scripps Health.
2Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4
Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119